NCT06030037
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06030037
Title Pembrolizumab/Lenvatinib With and Without Responder-derived FMT in Relapsed/Refractory Melanoma
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors Diwakar Davar
Indications
Therapies
Age Groups: adult | senior
Covered Countries

Facility Status City State Zip Country Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field